Fosun Pharma signs licensing deal with Henlius Biotech for serplulimab
Fosun Pharma has signed an exclusive US licensing agreement with Shanghai Henlius Biotech for commercializing the latter’s serplulimab, an anti-PD-1 monoclonal antibody (mAb). The financial terms of the licensing deal were not disclosed. As per the terms of the agreement, Fosun Pharma will hold the right to commercialize serplulimab upon US Food and Drug Administration’s […]